Quest Diagnostics Clinical Laboratories, Inc.

Quest Diagnostics Clinical Laboratories, Inc., a subsidiary of Quest Diagnostics Incorporated, delivers drug and alcohol specimen laboratory analysis and clinical diagnostic testing to federal agencies as a prime contractor on a non-competitive, full-and-open basis, with no SBA set-aside activity. The company is a large for-profit organization headquartered in Secaucus, New Jersey, competing across 2,840 prime awards (100% of its federal prime footprint) worth a combined $1.02 billion in potential value, supported by a secondary sub footprint of 5 sub-awards. The parent company operates nationwide with performance locations including Secaucus and Collegeville, Pennsylvania; Washington, DC; Denver, Colorado; and El Paso, Texas.

Quest Diagnostics' federal capability portfolio centers on clinical laboratory testing for controlled substances—marijuana (THC), cocaine, opioids, amphetamines, phencyclidine, and fentanyl—through analysis of urine, oral, and breath specimens. Representative work includes a $3.9 million single-award Indefinite Delivery Indefinite Quantity contract with the Department of the Interior's Interior Business Center (awarded February 1, 2023, through January 31, 2028) that has generated over $1.6 million in delivery orders across seven named federal agencies: U.S. Marshals Service Human Resources Division, Court Services and Offender Supervision Agency, U.S. Secret Service, Bureau of Alcohol Tobacco Firearms and Explosives, Department of Justice Bureau of Prisons, Department of Health and Human Services, and Centers for Disease Control and Prevention. Individual delivery orders under that IDIQ range from approximately $1,800 to $560,946.55. Recent concrete delivery orders include a $557,103.45 order to the Interior Business Center (April 1, 2026), a $5,000 order to CSOSA (March 30, 2026), and a $16,779 order to U.S. Marshals Service Human Resources Division (March 1, 2026). Secondary capability includes COVID-19 testing and specialty lab testing services, as shown by a $129,022.84 purchase order with Department of Veterans Affairs Veterans Integrated Service Network 17 for specialty lab testing (June 1, 2022) and a $92,922 CDC purchase order for comprehensive diagnostic testing solutions (September 25, 2023).

Customer concentration is extreme and skews toward military health systems. The top five customer agencies by award count and potential value account for 56% and 68% of awards, respectively—Department of the Army Medical Command leads decisively with 581 awards and $573.9 million combined potential value, followed by Department of Health and Human Services Indian Health Service (445 awards, $17.6 million), Department of the Navy Bureau of Medicine and Surgery (345 awards, $84.9 million), Department of the Air Force Air Combat Command (132 awards, $9.9 million), and Department of the Army (104 awards). The two rankings diverge markedly: while Army Medical Command dominates both volume and dollars, Navy Bureau of Medicine and Surgery ranks second in dollars but third in count, signaling larger individual Navy orders; conversely, HHS Indian Health Service places second in volume but third in dollars. Across all 106 named customer agencies, 2,610 awards fall under NAICS Medical Laboratories (92% of awards) and 2,686 under PSC Reference Laboratory Testing.

The vendor holds five major parent vehicles anchoring task-order activity. The largest is Indefinite Delivery Contract W81K0406D0001 with 628 task orders worth $109.6 million combined potential value, followed by Medical Laboratory Testing and Analysis Services with 587 task orders ($58.5 million), Indefinite Delivery Contract W81K0410D0011 with 298 task orders ($63 million), Indefinite Delivery Contract W81K0412D0013 with 265 task orders ($46.7 million), and Blanket Purchase Agreement HHSI248201100013B with 319 task orders ($5.5 million). All vehicle activity reflects firm fixed-price, non-set-aside procurement.

Recent activity has declined sharply. Awards per year dropped from 10 in 2023 to 5 in 2024 and 7 in 2025, with only 4 awards recorded for 2026 year-to-date—a contraction from historical norms established over the 46-year award record. Over the next twenty-four months, only 7 awards (combined potential value $1.4 million) face ultimate completion, presenting minimal recompete exposure. Service Contract Inventory reporting captures only $1.3 million in invoiced revenue across FY2022–FY2024 (8 SCI records, all as prime; zero sub-engagement), with FY2022 at $822 thousand (2.0 FTEs), FY2023 at $418 thousand (1.0 FTEs), and FY2024 at $51 thousand (1.2 FTEs)—a 94% decline from FY2022 to FY2024. This SCI-reported volume is a strict subset of federal service contracts above the $150,000 threshold and excludes goods, products, and micro-purchases; it does not represent the vendor's total federal revenue or enterprise revenue. Median government-paid hourly rates on SCI-reportable prime contracts run around $200.04 per hour, with rates ranging from $92.01 to $200.28 per hour. The vendor operates as a pure prime on SCI work (0% sub-hours share) and maintains no named subcontractor relationships in the SCI dataset.

In its sub footprint, Quest Diagnostics delivers drug and alcohol testing services and medical review officer support to Fluor Marine Propulsion on a Naval Nuclear Laboratory management and operations sub-award (July 31, 2025) and to KBR Services on the Medical Support Services Iraq prime (March 8, 2025).

The corporate structure identifies Phenopath Laboratories, PLLC as a named subsidiary of the parent Quest Diagnostics Incorporated. The parent company, not the subsidiary, holds the prime federal footprint. The subsidiary's federal work, if any, is not separately resolved in the source data.